Etienne Formstecher is appointed as CEO of Hybrigenics Services

Paris, 08 January 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical group listed on the Alternext market of Euronext Paris, today announces the promotion of Etienne Formstecher as Chief Executive Officer of Hybrigenics Services, its subsidiary dedicated to fee-for-service scientific studies on protein interactions. He will report to Remi Delansorne, CEO of Hybrigenics.

Etienne Forsmtecher, 39 years old, has first graduated as engineer from Ecole Polytechnique (France) and subsequently obtained a PhD in Molecular and Cellular Pharmacology from Pierre and Marie Curie University (Paris 6). He joined Hybrigenics in 2002 as research project leader. In 2006, he founded the Scientific Projects team of the protein interaction services division and, in addition, was appointed Head of Marketing and Sales in 2008. Since the creation of Hybrigenics Services as a fully-owned subsidiary in 2010, Etienne Formstecher has been serving as Deputy General Manager in charge of Marketing, Sales and Scientific Projects.

"*The challenge facing Hybrigenics Services, the world leader in yeast-based protein interaction services, will be to explore and implement commercial, technological and business opportunities to fuel the next steps of sustainable organic or external growth*," said Etienne Formstecher, Hybrigenics Services' CEO.

"*Hybrigenics Services has sailed on a good tack in 2013 with the launch of a new service to discover interactions between proteins and small molecules, and with the acquisition of the yeast-based activities of Dualsystems Biotech, its main competitor. It is the right timing to further empower Etienne and his team of experienced scientists and executives who have made these successes possible,*" said Remi Delansorne, Hybrigenics' CEO.

About Hybrigenics Services
Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary of Hybrigenics, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

About Hybrigenics
Hybrigenics SA (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.
Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol is currently being tested in chronic lymphocytic leukemia patients.
Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.
Hybrigenics also provides state-of-the-art genomic services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing.
Hybrigenics Corp., based in Cambridge, Mass., is a fully-owned American subsidiary of Hybrigenics SA.

***

HYBRIGENICS is listed on the Alternext market of Euronext Paris

ISIN: FR0004153930
Ticker: ALHYG

Hybrigenics
Rémi Delansorne
CEO
Tel.: +33 (0)1 58 10 38 00
investors@hybrigenics.com

NewCap.
Financial communication
Julien Perez / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
hybrigenics@newcap.fr